SCHEMBL10195778

SCHEMBL10195778

O=C1C=C(NCc2ccccc2)c2ccccc2C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 1.00
KMT2A Q03164 4/20 1.00
LMNA P02545 4/20 1.00
BLM P54132 4/20 1.00
KDM4E B2RXH2 4/20 1.00
MEN1 O00255 3/20 1.00
NPSR1 Q6W5P4 3/20 1.00
L3MBTL1 Q9Y468 3/20 1.00
ALDH1A1 P00352 3/20 1.00
NSD2 O96028 3/20 1.00
RAB9A P51151 2/20 1.00
HKDC1 Q2TB90 2/20 1.00
POLB P06746 2/20 1.00
THRB P10828 2/20 1.00
GALK1 P51570 1/20 1.00
PLEC Q15149 1/20 1.00
APAF1 O14727 5/20 0.59
CASP3 P42574 5/20 0.59
SENP8 Q96LD8 5/20 0.59
SENP7 Q9BQF6 5/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15690641 0.88 MAPT (0.78) MAPTKMT2ALMNABLMKDM4E
SCHEMBL30991482 0.88 MAPT (0.78) MAPTKMT2ALMNABLMKDM4E
SCHEMBL2556802 0.83 MEN1 (0.70) MAPTKMT2ALMNABLMKDM4E
SCHEMBL15690511 0.77 MAPT (0.62) MAPTKMT2ALMNABLMKDM4E
SCHEMBL9334488 0.76 MEN1 (0.61) MAPTKMT2ALMNABLMKDM4E
SCHEMBL15700128 0.76 ALDH1A1 (0.60) MAPTKMT2ALMNABLMKDM4E
SCHEMBL15700149 0.76 MAPT (0.60) MAPTKMT2ALMNABLMKDM4E
SCHEMBL6409344 0.74 MAPT (1.00) MAPTKMT2ALMNABLMKDM4E
SCHEMBL30587682 0.74 MAPT (1.00) MAPTKMT2ALMNABLMKDM4E
SCHEMBL29226600 0.74 RAB9A (0.58) MAPTKMT2ALMNABLMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9073941-B2 Compounds and methods for treating tuberculosis infection ACADEMIA SINICA (TW) 2015-07-07 US disclosed
US-9073941-B2 Compounds and methods for treating tuberculosis infection ACADEMIA SINICA (TW) 2015-07-07 US disclosed
US-20130158037-A1 COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION ACADEMIA SINICA (TW) 2013-06-20 US disclosed
US-20130158037-A1 COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION ACADEMIA SINICA (TW) 2013-06-20 US disclosed
WO-2012006104-A2 COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION Academia Sinica, Taiwan (TW) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158037-A1 COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION TALDO1, PGD, DLD MAPT 3251/4885KMT2A 2118/4885LMNA 1052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.